CNS Drugs : Impact Factor & More
eISSN: 1179-1934pISSN: 1172-7047
Share this on:
Key Metrics
CiteScore 
9.8
Eigenfactor
0.005 - 0.01
Impact Factor
5 - 10
SJR
Q1Neurology (clinical)
SNIP
1.87
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on CNS Drugs
CNS Drugs Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
SJR
| Overview | |
| Publisher | ADIS INT LTD |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1994 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in CNS Drugs ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in CNS Drugs
Opioid Use Disorder Treatment Gaps and Emerging Therapeutics to Address Them.
- 1 Jul 2026
- CNS drugs
Effect of DL-3-n-Butylphthalide on Cerebral Hypoperfusion Due to Atherosclerotic Stenosis: A Multicenter, Double-Blind, Randomized Controlled, Preliminary Trial.
- 1 Jul 2026
- CNS drugs
Cannabidiol Use in Developmental and Epileptic Encephalopathies: A Syndrome- and Age-Stratified Systematic Review and Meta-analysis.
- 1 Jul 2026
- CNS drugs
Clinical Predictors of Antidepressant Effects of Ketamine and Esketamine in Treatment-Resistant Unipolar and Bipolar Depression: A Systematic Review.
- 1 Jul 2026
- CNS drugs
The Evolving Pharmacological Landscape for Paediatric and Adult ADHD.
- 1 Jul 2026
- CNS drugs
The Discovery of Cenobamate: A Drug with High Efficacy in Drug-Resistant Epilepsy.
- 1 Jul 2026
- CNS drugs
Opioid Use Disorder Treatment Gaps and Emerging Therapeutics to Address Them.
- 1 Jul 2026
- CNS drugs
Effect of DL-3-n-Butylphthalide on Cerebral Hypoperfusion Due to Atherosclerotic Stenosis: A Multicenter, Double-Blind, Randomized Controlled, Preliminary Trial.
- 1 Jul 2026
- CNS drugs
Cannabidiol Use in Developmental and Epileptic Encephalopathies: A Syndrome- and Age-Stratified Systematic Review and Meta-analysis.
- 1 Jul 2026
- CNS drugs
Clinical Predictors of Antidepressant Effects of Ketamine and Esketamine in Treatment-Resistant Unipolar and Bipolar Depression: A Systematic Review.
- 1 Jul 2026
- CNS drugs
The Evolving Pharmacological Landscape for Paediatric and Adult ADHD.
- 1 Jul 2026
- CNS drugs
The Discovery of Cenobamate: A Drug with High Efficacy in Drug-Resistant Epilepsy.
- 1 Jul 2026
- CNS drugs
FAQs on CNS Drugs
How long has CNS Drugs been actively publishing? 
What is the publishing frequency of CNS Drugs?
How many articles did CNS Drugs publish last year?
What is the eISSN & pISSN for CNS Drugs?
What is Citescore for CNS Drugs?
What is SNIP score for CNS Drugs?
What is the SJR for CNS Drugs?
Who is the publisher of CNS Drugs?
Check if your manuscript is a good match for
undefined
Upload your manuscript to get recommendations of journals
that have published papers similar to your manuscript
Drag and drop your file here
We accept manuscripts in English. File format: .doc and .docx | Maximum size: 10 MB | Word count: 200-300,000 words | File length: less than 100 pages
Do not have a manuscript right now? Use an abstract or summary
Your document is 100% secure & confidential We use 256-bit encryption for total security and
ISO/IEC 27001:2013 Certified
What all does the report include
01. Degree of Match
02. Common Topics
03. Additional
Recommendations
Recommendations